Obsidian and Galera Announce Merger Agreement with $350 Million Private Placement Plan

Obsidian Therapeutics and Galera Therapeutics have announced a definitive merger agreement, alongside plans for a $350 million concurrent private placement. The companies disclosed the development on Tuesday, April 14, 2026, outlining their intention to combine resources and expertise to advance their respective therapeutic pipelines.

As part of the agreement, the two biotechnology firms aim to leverage their combined capabilities in drug development. The $350 million private placement will provide additional funding to support ongoing research initiatives and operational needs following the merger. Both companies specialize in developing innovative therapies targeting unmet medical needs, with Obsidian focusing on engineered cell and gene therapies and Galera concentrating on treatments for radiation-induced toxicities and other conditions. Further details regarding the timeline for finalizing the merger or specific terms of the private placement were not immediately available.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 14, 2026

Author

GOAI